TAMPA, Fla.--(BUSINESS WIRE)--Aug. 11, 2005--Nanobac Life Sciences, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that Mission Pharmacal Company, a global pharmaceutical company and leading kidney stone disease reference laboratory, executed an observation rights agreement with Nanobac Life Sciences to observe a multi-center collaboration involving researchers from Nanobac, the University of California, San Francisco (UCSF), and NASA's Johnson Space Center, to study kidney stone formation. As announced previously, the multi-disciplinary team will apply the same type of instrumentation used to analyze moon rocks and particles collected from space to analyze mineralized particles and stones collected from kidney stone patients. The team will attempt to find early events in stone formation and to verify whether Calcifying Nano-Particles, also known as Nanobacteria, are the initiators of kidney stone formation. Terms of the agreement were not disclosed.

"We are very pleased that the global leader in kidney stone diagnostics and treatment has taken note of our science and wishes to observe this exciting study," stated Grant Carlson, Nanobac's President and Chief Operating Officer. "Mission Pharmacal with its world-class reference laboratory and wide-ranging product portfolio is uniquely positioned to bring new diagnostics, dietary supplements, and new therapeutics to the urology community. We are hopeful that our studies will change the way kidney stones are detected and ultimately treated."

Even though some progress has been made in understanding kidney stone formation, more needs to be known about its etiology. Researchers from Nanobac have shown that virtually all kidney stones contain Calcifying Nano-Particles, also referred to as "Nanobacteria." Nanobac researchers have also shown that these particles are powerful mediators of plaque formation and stones.

"Mission's growth as a pharmaceutical company and its future success stories can be attributed to preparedness, anticipating the changing health needs of the world. This commitment has kept Mission at the forefront of bringing new technologies to the medical community," stated Dan Crawford, Director of Urological Products at Mission Pharmacal Company. "We have been watching the research and supporting evidence that Nanobacteria or Calcifying Nano-particles may be implicated in kidney stone formation. We are excited to take a front row seat to observe this innovative and potentially groundbreaking research."

The collaboration brings together Nanobac's expertise in Calcifying Nano-Particles, with one of the leading urologists in the field of kidney stone disease, Dr. Marshall Stoller from UCSF. Through Nanobac's Space Act Agreement with NASA, Dr. Neva Ciftcioglu, Nanobac's Director of Science and researcher at NASA, and a team of biomaterial researchers, headed by Dr. David McKay, will apply some of the world's most sophisticated instruments for studying mineralized samples.

The economic costs of kidney stones are enormous. In the U.S., more than half a million people will develop kidney stones this year and 7 to 10 of every 1,000 hospital admissions are due to kidney stones. Men appear to be afflicted with kidney stones more often than women, with the ratio being about 3 to 1. In addition, those who develop kidney stones have a 50% risk of having another stone within 5-10 years. The maximum incidence occurs in the 30-50 year old age group.

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and treatment of Calcifying Nano-Particles, also referred to as "Nanobacteria." The Company's pioneering research is establishing the pathogenic role of Nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac has identified and established two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacteria antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nano-particle infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our websites at: http://www.nanobaclifesciences.com or http://www.nanobacsciences.com .

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.